Mark Roithmayr is the retired CEO of the Alzheimer’s Drug Discovery Foundation (ADDF), where he led a venture philanthropy model focused on accelerating the development of therapies for Alzheimer’s disease and related dementias. He brings deep experience in nonprofit leadership, governance, and advancing science through cross-sector collaboration.

In retirement, he advises a small number of CEOs and mission-driven organizations on leadership, venture philanthropy strategy, and executive development, and is honored to serve on the Board of Directors of Voices of Alzheimer’s.